Obesity is a global health crisis with profound clinical and societal consequences, contributing to increased risks of chronic illness and related mortality.1 Despite being recognised as a disease by ...

Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter.

In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the preceding trading day.

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...

Pharmaceutical giant Eli Lilly announced a price cut for its drug, Zepbound, for people who aren't using insurance. CBS News' Nancy Chen reports on the qualifications for the discount and what the ...

In today's Pharmalittle roundup, we're reading about a Sarepta setback with its Duchenne drug, the FDA workload causing a ...

With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of ...

While polio often struck children, older people were not immune. The disease consigned former President Franklin D. Roosevelt ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

The Healthcare Select Sector SPDR Fund ETF is a sector ETF offering exposure to large-cap U.S. healthcare companies. Learn ...

Officials at the FDA say they want to speed up approvals for new drugs and devices using tech like the new "Elsa" AI system. More news is on other uses of AI in health care, Eli Lilly refusing to work ...